Literature DB >> 1725313

Intracellular signaling pathway of endothelin-1.

K Iijima1, L Lin, A Nasjletti, M S Goligorsky.   

Abstract

The intracellular signaling pathway of endothelin-1 (ET-1) was studied in individual mesangial cells (MCs) and vascular smooth muscle cells (VSMCs) using microspectrofluorimetry of fura-2 ([Ca2+]i), SPQ ([Cl-]i), and bisoxonol (membrane potential). ET-1 elicited a five-fold increase in [Ca2+]i that showed immediate and sustained phases. Both the Ca(2+)-free medium and nifedipine pretreatment curtailed the sustained phase of the response to ET-1. ET-1 resulted in sustained membrane depolarization of MCs and VSMCs. This depolarization was not attributed to Na influx, as Na-free medium did not abolish it. A Cl(-)-channel inhibitor, IAA-94, blunted the depolarization and sustained elevation of [Ca2+]i in response to ET-1. In aortic rings, both nifedipine and IAA-94 attenuated ET-1-induced contraction. No additivity in the effect of nifedipine and IAA-94 was detected. Studies of SPQ fluorescence changes induced by ET-1 revealed an immediate and sustained increase in fluorescence intensity consistent with the decrease in [Cl-]i. The sustained but not immediate increase in SPQ fluorescence was virtually abolished in Ca(2+)-free medium with or without pretreatment with the intracellular Ca2+ chelator BAPTA. In conclusion, we hypothesize that ET-1 results in Ca2+ mobilization and Ca(2+)-dependent and -independent activation of Cl- channels. Ensuing Cl- efflux causes membrane depolarization and, in turn, activation of voltage-gated Ca2+ channels in MCs and VSMCs. The latter results in sustained elevation of [Ca2+]i that is indispensable for the full-scale contractile response to ET-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725313     DOI: 10.1097/00005344-199100177-00040

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Lysophosphatidylcholines activate G2A inducing G(αi)₋₁-/G(αq/)₁₁- Ca²(+) flux, G(βγ)-Hck activation and clathrin/β-arrestin-1/GRK6 recruitment in PMNs.

Authors:  Samina Y Khan; Nathan J D McLaughlin; Marguerite R Kelher; Phillip Eckels; Fabia Gamboni-Robertson; Anirban Banerjee; Christopher C Silliman
Journal:  Biochem J       Date:  2010-11-15       Impact factor: 3.857

3.  Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

Authors:  Inés Pulido; Stephen Ollosi; Salvador Aparisi; Jeffrey H Becker; Alicia Aliena-Valero; Marta Benet; María L Rodríguez; Adrián López; Eva Tamayo-Torres; Lourdes Chuliá-Peris; Juan Carlos García-Cañaveras; Margaret Soucheray; Annika V Dalheim; Juan B Salom; Wei Qiu; Simon Kaja; Javier Alcácer Fernández-Coronado; Sandra Alandes; Javier Alcácer; Fátima Al-Shahrour; Jeffrey A Borgia; Oscar Juan; Michael I Nishimura; Agustín Lahoz; Julián Carretero; Takeshi Shimamura
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

4.  Protein kinase C inhibitors enhance endothelin-1 and attenuate vasopressin and angiotensin II evoked [Ca2+]i elevation in the rat cardiomyocyte.

Authors:  Y Xu; L Sandirasegarane; V Gopalakrishnan
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.